WallStSmart

Boston Scientific Corp (BSX)vsENvue Medical Inc. (FEED)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Boston Scientific Corp generates 747535% more annual revenue ($20.07B vs $2.69M). BSX leads profitability with a 14.4% profit margin vs -2.5%. BSX earns a higher WallStSmart Score of 63/100 (C+).

BSX

Buy

63

out of 100

Grade: C+

Growth: 8.0Profit: 6.5Value: 8.7Quality: 5.5
Piotroski: 4/9

FEED

Hold

41

out of 100

Grade: D

Growth: 7.3Profit: 2.0Value: 5.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXUndervalued (+1.2%)

Margin of Safety

+1.2%

Fair Value

$70.62

Current Price

$69.78

$0.84 discount

UndervaluedFair: $70.62Overvalued

Intrinsic value data unavailable for FEED.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX4 strengths · Avg: 8.3/10
Market CapQuality
$101.28B9/10

Large-cap with strong market position

PEG RatioValuation
0.758/10

Growing faster than its price suggests

Revenue GrowthGrowth
15.9%8/10

15.9% revenue growth

Free Cash FlowQuality
$1.01B8/10

Generating 1.0B in free cash flow

FEED2 strengths · Avg: 10.0/10
Price/BookValuation
0.1x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
92.0%10/10

Revenue surging 92.0% year-over-year

Areas to Watch

BSX1 concerns · Avg: 4.0/10
P/E RatioValuation
35.1x4/10

Premium valuation, high expectations priced in

FEED4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.31M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-30.5%2/10

ROE of -30.5% — below average capital efficiency

Free Cash FlowQuality
$-2.00M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on Market Cap, PEG Ratio, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.

Bull Case : FEED

The strongest argument for FEED centers on Price/Book, Revenue Growth. Revenue growth of 92.0% demonstrates continued momentum.

Bear Case : BSX

The primary concerns for BSX are P/E Ratio.

Bear Case : FEED

The primary concerns for FEED are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

BSX profiles as a growth stock while FEED is a hypergrowth play — different risk/reward profiles.

FEED carries more volatility with a beta of 2.28 — expect wider price swings.

FEED is growing revenue faster at 92.0% — sustainability is the question.

BSX generates stronger free cash flow (1.0B), providing more financial flexibility.

Bottom Line

BSX scores higher overall (63/100 vs 41/100) and 15.9% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

ENvue Medical Inc.

HEALTHCARE · MEDICAL DEVICES · USA

ENvue Medical Inc. (FEED) is a forward-thinking healthcare technology firm committed to revolutionizing patient care management through advanced medical devices and software solutions. By harnessing innovative technology, ENvue Medical focuses on optimizing recovery processes and improving health outcomes across various clinical settings. The company's robust product pipeline, coupled with strategic collaborations, positions it well to capitalize on the growth of the healthcare industry, presenting a compelling investment opportunity for institutional investors seeking exposure to the dynamic fields of medical device innovation and digital health advancements.

Want to dig deeper into these stocks?